Pharmaceutical

OCT-461201 by Oxford Cannabinoid Technologies for Visceral Pain: Likelihood of Approval

OCT-461201 is under clinical development by Oxford Cannabinoid Technologies and currently in Phase I for Visceral Pain.

Jun 18, 2024 - 04:00
OCT-461201 is under clinical development by Oxford Cannabinoid Technologies and currently in Phase I for Visceral Pain.
Read the original article

Tags:

Previous Article

MAS-825 by Novartis for Coronary Artery Disease (CAD) (Ischemic Heart Disease): ...

Next Article

OCT-461201 by Oxford Cannabinoid Technologies for Neuropathic Pain (Neuralgia): ...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: FDA approves first treatment for skin condition that causes persistent wounds, a redosable gene therapy

STAT+: FDA approves first treatment for skin condition ...

May 19, 2023

Johnson & Johnson submits sNDA for SPRAVATO to treat depression

Johnson & Johnson submits sNDA for SPRAVATO to treat de...

Jul 24, 2024

Treatment options for Crohn’s disease expand after Rinvoq approval

Treatment options for Crohn’s disease expand after Rinv...

May 20, 2023